



Universiteit
Leiden
The Netherlands

Keyhole limpet hemocyanin challenge model for studying adaptive immune system responses in early-phase clinical drug development

Saghari, M.

Citation

Saghari, M. (2024, December 17). *Keyhole limpet hemocyanin challenge model for studying adaptive immune system responses in early-phase clinical drug development*. Retrieved from <https://hdl.handle.net/1887/4172487>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4172487>

Note: To cite this publication please use the final published version (if applicable).

APPENDICES

CURRICULUM VITAE

Mahdi Saghari was born on the 11th of October 1989 in Herat, Afghanistan. After completing bilingual vwo at secondary school CVO Farelcollege (Ridderkerk, the Netherlands) in 2008, he studied Medicine at Erasmus University Rotterdam (Rotterdam, the Netherlands). He obtained his bachelor's degree in Medicine in 2012. Due to his interest in both academic research and medicine he simultaneously studied Neuroscience and Medicine, for which he obtained a Master's degree in 2014 and 2017, respectively. His primary focus during Neuroscience was the preclinical development of novel antisense oligonucleotide (ASO) therapy for Angelman syndrome in the lab of prof. dr. Ype Elgersma at the Erasmus Medical Center (Rotterdam, the Netherlands). His research served as the starting point for further evaluation of ASO therapy in Angelman syndrome, with promising results (Milazzo et al. 2021, DOI: 10.1172/jci.insight.145991).

Upon obtaining his medical degree in 2017, he started his career as a research physician and project leader at the Centre for Human Drug Research (CHDR, Leiden, the Netherlands). Here Mahdi began his PhD trajectory as described in this thesis under supervision of dr. M. Moerland, prof. dr. R. Rissmann and prof. dr. J. Burggraaf. In addition to performing clinical research described in this PhD thesis, he also contributed to many other clinical studies across different therapeutic areas including dermatology, immunology and cardiology. Whilst working at CHDR, he became a board-certified Clinical Pharmacologist in 2022.

In 2023 Mahdi worked as a medical intern at the dermatology department of the Admiraal de Ruyter ziekenhuis (ADRZ, Goes, the Netherlands). Since April 2024 he works as a medical intern in occupational health medicine at HumanCapitalCare B.V. (Capelle aan den IJssel, the Netherlands), with the aim to become an occupational health physician.

LIST OF PUBLICATIONS

Rousel, J., Nädäban, A., **Saghari, M.**, Pagan, L., Zhuparris, A., Theelen, B., Gambrah, T., van der Wall, H. E. C., Vreeken, R. J., Feiss, G. L., Niemeyer – van der Kolk, T., Burggraaf, J., van Doorn, M. B. A., Bouwstra, J. A., Rissmann, R. (2023). Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition. *Experimental Dermatology*. <https://doi.org/10.1111/exd.14952>

Rousel, J., **Saghari, M.**, Pagan, L., Nädäban, A., Gambrah, T., Theelen, B., de Kam, M. L., Haakman, J., van der Wall, H. E. C., Feiss, G. L., Niemeyer – van der Kolk, T., Burggraaf, J., Bouwstra, J. A., Rissmann, R., van Doorn, M. B. A. (2023) treatment with the topical antimicrobial peptide omiganan in mild-to-moderate facial seborrheic dermatitis versus ketoconazole and placebo: results of a randomized controlled proof-of-concept trial. *International Journal of Molecular Sciences*. <https://doi.org/10.3390/ijms241814315>

Saghari, M., Gal, P., Grievink, H.W., Klaassen, E.S., Zhuparris, A., Itano, A., Bodmer, M., McHale, D., Moerland, M. (2023). Evaluation of single-strain *Prevotella histicola* on KLH-driven immune responses in healthy volunteers: a randomized controlled trial with EDP1815. *Medicine in Microecology*. <https://doi.org/10.1016/j.medmic.2023.100088>

Itano, A., Maslin, D., Ramani, K., Mehraei, G., Carpenter, N., Cormack, T., **Saghari, M.**, Moerland, M., Troy, E., Caffry, W., Wardwell-Scott, L., Abel, S., McHale, D., & Bodmer, M. (2023). Clinical translation of anti-inflammatory effects of *Prevotella histicola* in Th1, Th2, and Th17 inflammation. *Frontiers in Medicine*, 10. <https://doi.org/10.3389/fmed.2023.1070433>

ten Voorde, W., **Saghari, M.**, Boltjes, J., de Kam, M. L., Zhuparris, A., Feiss, G., Buters, T. P., Prens, E. P., Damman, J., Niemeyer-van der Kolk, T., Moerland, M., Burggraaf, J., van Doorn, M. B. A., & Rissmann, R. (2023). A multimodal, comprehensive characterization of a cutaneous wound model in healthy volunteers. *Experimental Dermatology*. <https://doi.org/10.1111/exd.14808>

Saghari, M., Gal, P., Grievink, H. W., Klaassen, E. S., Itano, A., McHale, D., & Moerland, M. (2022). Impact of oral administration of single strain *Lactococcus lactis* spp. *cremoris* on immune responses to keyhole limpet hemocyanin

immunization and gut microbiota: A randomized placebo-controlled trial in healthy volunteers. *Frontiers in Immunology*, 13. <https://doi.org/10.3389/fimmu.2022.1009304>

Saghari, M., Jansen, M. A. A., Grievink, H. W., Rissmann, R., & Moerland, M. (2022). Characterization of KLH-driven immune responses in clinical studies: a systematic review. *Frontiers in Drug Discovery*, 2. <https://doi.org/10.3389/fddsv.2022.992087>

Saghari, M., Gal, P., Gilbert, S., Yateman, M., Porter-Brown, B., Brennan, N., Quarantino, S., Wilson, R., Grievink, H. W., Klaassen, E. S., Bergmann, K. R., Burggraaf, J., Doorn, M. B. A., Powell, J., Moerland, M., & Rissmann, R. (2022). OX40L inhibition suppresses KLH-DRIVEN immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005. *Clinical Pharmacology & Therapeutics*, 111(5), 1121–1132. <https://doi.org/10.1002/cpt.2539>

Saghari, M., Gal, P., Ziagos, D., Burggraaf, J., Powell, J. F., Brennan, N., Rissmann, R., Doorn, M. B. A., & Moerland, M. (2021). A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man. *British Journal of Clinical Pharmacology*, 87(4), 1953–1962. <https://doi.org/10.1111/bcp.14588>

Gal, P., Klaassen, E. S., Bergmann, K. R., **Saghari, M.**, Burggraaf, J., Kemme, M. J. B., Sylvest, C., Sørensen, U., Bentzen, B. H., Grunnet, M., Diness, J. G., & Edvardsson, N. (2020). First clinical study with AP30663 - a KCa2 channel inhibitor in development for conversion of atrial fibrillation. *Clinical and Translational Science*, cts.12835. <https://doi.org/10.1111/cts.12835>

In 't Veld, A. E., Grievink, H. W., **Saghari, M.**, Stuurman, F. E., de Kam, M. L., de Vries, A. P. J., de Winter, B. C. M., Burggraaf, J., Cohen, A. F., & Moerland, M. (2019). Immunomonitoring of tacrolimus in healthy volunteers: the first step from PK- to PD-based therapeutic drug monitoring? *International Journal of Molecular Sciences*, 20(19). <https://doi.org/10.3390/ijms20194710>

ACKNOWLEDGEMENTS

I would like to express my profound gratitude to my promoter, Koos, and my co-promoters, Matthijs and Robert, for their steadfast support and invaluable critiques throughout the course of my PhD trajectory. Their dedication to academic rigor and meticulous attention to detail have played a pivotal role in shaping this dissertation. I'm also extremely grateful to my daily supervisor, Pim, whose expertise in academic research and consistent support have been invaluable. Furthermore, I wish to acknowledge my fellow PhD candidates for their camaraderie and for the stimulating discussions that have inspired me throughout my academic journey. Their collective insights and encouragement have been integral to my research experience.

Many thanks go to all colleagues at the Centre for Human Drug Research (CHDR) across all departments – including recruitment, the screening unit, nursing staff, adminCRU, data management, data programming, statistics, laboratory, clinical trial assistants, and research assistants. This thesis would not have been possible without the involvement of each and every colleague at CHDR. Their assistance, dedication, and hard work – from the conceptualization phase to the reporting and publication of results of each trial – have been invaluable and are deeply appreciated.

I am forever grateful for Gökçe, my loving, caring, and patient spouse. Your continuous support and belief in my academic pursuits have been instrumental in my success. My beloved daughter Mira, you have been and will always remain a beacon of light during moments of doubt. I must also express my deepest appreciation for my parents and siblings, Reza, Masooma, and Toktam, your unconditional love and sacrifice have been the foundation of my resilience and success.

Additionally, a special shoutout to my close friends, Naim, Niluvar, Mejrem, and Poul, for the joy and laughter they brought throughout my years as a PhD candidate. Finally, I am especially grateful to my paranymphs, Hevy and Wouter, for their consistent support and resolute encouragement.